Business, energy, technology, markets and global industry news from Business News Today

HWK-016

PharmaDeviceNews HWK-016
Representative image of antibody-drug conjugate cancer research, illustrating the next-generation ADC platform strategy highlighted by Whitehawk Therapeutics at AACR 2026.
Pharma & Biotech

Can Whitehawk Therapeutics turn preclinical ADC depth into a real oncology pipeline advantage?

Whitehawk Therapeutics unveiled AACR 2026 data for three ADCs. Read what it means for pipeline differentiation, risk, and investor sentiment.

Read More
Pharma & Biotech

Whitehawk Therapeutics sharpens HWK-016 case as MUC16 emerges as a stronger ADC target in gynecologic cancers

Whitehawk Therapeutics says new MUC16 data support HWK-016 in gynecologic cancers. Read what this could change for ADC development.

Read More